NYSE: DGX · Industrial Applications and Services · 7 alerts · CIK 1022079
Share price
$262.21Close, Nov 16
Market cap
$28.8B
Shares outstanding
110.02MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Quest Diagnostics Inc filings on SEC EDGAR ↗
Quest Diagnostics SVP for Diagnostic Services Patrick Plewman Sells $3.02M of Stock
Patrick Plewman, SVP for Diagnostic Services, sold 11,717 shares of Quest Diagnostics Inc at $257.34 a share, worth $3.02M in total on Nov 9, 2026. Shares held after the trade: 14,684 (-4.2%).
Quest Diagnostics EVP Catherine T. Doherty Sells $5.48M of Stock
Catherine T. Doherty, EVP, sold 22,105 shares of Quest Diagnostics Inc at $245.45 to $251.24 a share (average $248.02) in 7 transactions, worth $5.48M in total on Nov 3, 2026. Shares held after the trade: 71,949 (-3.9%).
Quest Diagnostics Insider Gary M. Pfeiffer Sells $292K of Stock
Gary M. Pfeiffer sold 1,203 shares of Quest Diagnostics Inc at $243.00 a share, worth $292K in total on Oct 26, 2026. Shares held after the trade: 29,802 (-3.9%).
Quest Diagnostics reported net revenues of $3,097 million for the third quarter of 2026, an increase from $2,816 million in the prior year. Net income attributable to the company rose to $312 million, driven by higher operating income and lower interest expenses compared to the same period in 2025.
Quest Diagnostics disclosed a cybersecurity incident involving unauthorized access to its Quanum LSM system, which clients use for test orders and results. The company believes an unauthorized party accessed certain patient records and has notified federal law enforcement. The incident has not materially disrupted business operations or the company's ability to serve patients.
Quest Diagnostics reported third quarter 2026 revenues of $3.10 billion, a 10% increase year-over-year driven by strong organic growth across physician, hospital, and consumer channels. The company raised its full-year 2026 guidance for both revenue and EPS, citing productivity gains from automation and AI and expanding clinical care needs.
Term
Q3 2026
“We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI. Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population as well as the increasing number of people focused on prevention and wellness. With these growth trends and our strong performance, we are raising our revenue and EPS guidance for the full year.”